Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis

Click to increase image sizeClick to decrease image size

Author contributions

DF and EK performed data analysis and research design and wrote the paper. FT, PM, INS, MG, NK, MM and EEP were involved in data collection and patient management and reviewed the manuscript. ET and MAD reviewed the manuscript. AP and CK reviewed the majority of the pathology specimens and reviewed the manuscript.

Disclosure statement

Conflicts of interest EK: Consultancy: Janssen, Pfizer, Amgen Honoraria: Janssen, Pfizer, Takeda, Genesis Pharma, Amgen MG; Honoraria: Janssen, Genesis Pharma, Amgen, Karyopharm, Sanofi, GSK, Takeda, ET; Consultancy: Janssen, Amgen, Genesis Pharma, Celgene, Takeda, Sanofi; Honoraria: Novartis, Janssen, Takeda, Genesis Pharma, Amgen, Celgene, Sanofi, BMS, GSK; MAD: Honoraria: Takeda, BMS, Amgen, Beigene, Janssen. DF, FT, MG, MM, NK, PM, INS, EEP, AP, CK declare no conflicts of interest.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.